← Back to patent-cliff list
CAS 136612-71-0
2-ethynyl-1,3,5-trimethoxybenzene
Codes: RIGO-013
Application context (from source-drug indications)
Non-small cell lung cancerRigosertib SodiumAdenocarcinomaRigosertib Sodium营养不良性大疱性表皮松解Rigosertib SodiumMyelodysplastic syndromeRigosertib SodiumChronic myelomonocytic leukaemiaRigosertib SodiumPancreatic cancerRigosertib Sodium
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Rigosertib Sodium | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
4-(bromomethyl)-1-methoxy-2-nitrobenzene→2,4,6-trimethoxybenzaldehyde→(E)-2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)aniline→(E)-methyl 2-((2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)phenyl)amino)acetate→((4-methoxy-3-nitrobenzyl)thio)methanediamine hydrobromide→(4-methoxy-3-nitrophenyl)methanethiol→2-ethynyl-1,3,5-trimethoxybenzene→(E)-(4-methoxy-3-nitrobenzyl)(2,4,6-trimethoxystyryl)sulfane→(E)-2-methoxy-5-(((2,4,6-trimethoxystyryl)thio)methyl)aniline→2-(2,2-dibromovinyl)-1,3,5-trimethoxybenzene
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.